Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Amgen

Revenues up 2% despite competition for key products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen

3Q Revenues: $5.8 billion (+2%)

3Q Earnings: $2.0 billion (+8%)

YTD Revenues: $17.0 billion (+6%)

YTD Earnings: $5.8 billion (+13%)

Comments: Enbrel sales were flat at $1.5 billion impacted by competition and unfavorable changes in inventory levels. Neulasta sales decreased 5% to $1.2 billion due to lower unit demand. Aranesp sales were up 8% to $531 million driven by a shift by some U.S. dialysis customers from EPOGEN to Aranesp. Sensipar/Mimpara sales increased 18% to $415 million driven by net selling price and higher unit demand. XGEVA sales were up 4% to $394 million, and Prolia sales increased 18% to $379 million driven by higher unit demand.EPOGEN sales were down 31% to $335 million impacted by competition and a shift by some U.S. dialysis customers to Aranesp. KYPROLIS sales were up 34% to $183 million driven by higher unit demand. NEUPOGEN sales dropped 36% to $183 million impacted by competition in the U.S. Vectibix sales were up 24% to $164 million driven by higher unit demand. Nplate sales were up 10% to $151 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters